NPC1L1 and metabolic dysfunction-associated steatotic liver disease: Previous reports have shown high NPC1L1 expression in both the liver and intestine in rats, unlike mice, where NPC1L1 expression is predominantly observed in the intestine and undetectable in the liver (Garcia-Calvo et al., 2005), suggesting that ezetimibe’s effects on hepatic steatosis may be attributed, in part, to inhibiting NPC1L1 in the liver, highlighting a potential mechanism for its therapeutic benefits in NAFLD.